Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x100px

Document › Details

Mologen AG. (1/17/17). "Press Release: Convertible Bond Worth €4.99 Million Successfully Placed [Not for United States, Australia, Canada or Japan, et al.]". Berlin.

	Organisation	Mologen AG
	Group	Mologen (Group)
	Organisation 2	Global Derivative Trading GmbH (GDT)
	Product	investment banking
	Product 2	lefitolimod (MGN1703)
	Index term	Mologen–SEVERAL: credit, 201701–202501 convertible bonds €4.99m at 6% incl major shareholder GTD
	Person	Miller, Walter (Mologen 201604– CFO before Nuvisan Gmbh + Santhera Pharmaceuticals)
	Person 2	Nickolaus, Claudia (Medios 202304 Head of IR + Public Relations + ESG Commmunications formerly at Mologen)

Original document
accessed by [iito] on 2017-02-21

Record changed: 2023-06-05

Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x200px

More documents for Mologen (Group)

[1] Mologen AG. (12/3/19). "Press Release: Insolvency Filing [Not for publication or distribution in or into US, AU, CA or JP or any jurisdiction in which unlawful]". Berlin....
[2] Mologen AG. (8/5/19). "Press Release: Mologen AG Announces Top Line Data of Pivotal IMPALA Study in Metastatic Colorectal Cancer. Primary Endpoint Not Met". Berlin....
[3] Mologen AG. (3/27/19). "Press Release: Top Pharma Manager Stefan M. Manth, MD, to Become CEO of Mologen AG". Berlin....
[4] Mologen AG. (3/18/19). "Press Release: Early Departure of CEO". Berlin....
[5] Mologen AG. (1/17/19). "Press Release: Full Placement of Convertible Bond 2019/2027. Total Amount Issued: EUR2.7 Million, Maturity of 8 Years, Coupon of 6% p.a. [NOT FOR US, CA, JP, et al.]". Berlin....
[6] Mologen AG. (11/16/18). "Press Release: Mologen AG to Retain Rights to Lefitolimod – Termination of Negotiations with Oncologie Inc. and Assessment of All Strategic Options in the Light of a Likely Read-out of the Pivotal Phase III IMPALA Trial in 2019"....
[7] Mologen AG. (11/12/18). "Press Release: Lefitolimod – First Clinical Data in Combination with a Checkpoint Inhibitor and further Preclinical Results Presented at SITC 2018". Berlin....
[8] Convert Pharmaceuticals S.A.. (11/8/18). "Press Release: Convert Pharmaceuticals Appoints Mariola Söhngen as New CEO"....
[9] Mologen AG. (11/8/18). "Press Release: Implementation of Financing Measures and Publication of Study Results". Berlin....
[10] Mologen AG. (9/27/18). "Press Release: Mologen AG Completes Capital Increase with Gross Proceeds of around EUR8 Million [NOT FOR RELEASE IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, et al.]". Berlin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]